Novacyt's molecular testing division, Primerdesign, has entered into a clinical assay development contract with GenePOC, a Canada-based company which specialises in the development and manufacture of molecular diagnostic devices for the detection of infectious diseases closer to the patient.
Under the terms of the services agreement, Primerdesign will develop a triplex molecular diagnostic assay to identify influenza A, influenza B and respiratory syncytial virus A and B (RSV A and B) which will subsequently be run on GenePOC's revogene instrument.
GenePOC will seek regulatory clearance for the assay in the US through the US Food and Drug Administration (FDA) and CE-IVD marking in Europe under the In Vitro Diagnostic Directive.
Graham Mullis, group CEO of Novacyt, said: "I am delighted that we are entering into this clinical development agreement with GenePOC, a leader in the provision of high-speed, high-quality and on-the-spot molecular diagnostic devices to healthcare practitioners. This marks our first significant business-to-business clinical development contract win in 2018 and adds further momentum to our business-to-business segment following material contract wins in China for both Primerdesign and NOVAprep."
At 8:48am: (LON:NCYT) Novacyt S.a. Eur115th Cdi share price was +1p at 66p